查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球癌症免疫疗法市场研究报告 - 行业分析、规模、份额、增长、趋势及2023年至2030年预测
市场调查报告书
商品编码
1306946

全球癌症免疫疗法市场研究报告 - 行业分析、规模、份额、增长、趋势及2023年至2030年预测

Global Cancer Immunotherapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

据预测，到2030年，全球癌症免疫治疗市场需求将从2022年的1170.9亿美元增长至2369.3亿美元，2023-2030年的复合年增长率将达到9.21%。

癌症免疫疗法，或免疫肿瘤学，是指利用人体免疫系统的非凡能力来对抗癌症的一种治疗方法。免疫系统是人体抵御包括癌症在内的各种疾病的固有防御机制。它由各种细胞、组织和器官组成，共同识别并消灭异常细胞，包括癌细胞。

市场动态：

癌症免疫疗法市场的大幅增长有几个关键因素。首先，全球癌症发病率不断上升，推动了对有效治疗方案的需求。免疫疗法具有靶向各类癌症的潜力，已成为一种前景广阔的解决方案。其次，免疫疗法的良好临床效果，包括提高生存率和长期疗效，促进了免疫疗法的应用。第三，免疫疗法技术的进步，如新型靶点的发现和联合疗法的开发，提高了治疗效果。政府倡议、资金支持和简化的监管流程也在推动市场增长方面发挥了重要作用。此外，制药公司与研究机构之间的合作和伙伴关系也加速了该领域的创新。投资的增加和市场竞争的加剧促进了多种免疫治疗药物的开发。针对不同患者量身定制治疗方案的个性化医疗方法进一步推动了市场的发展。此外，免疫治疗药物的适应症和批准范围的扩大也拓宽了潜在的患者人群。总体而言，这些因素加上正在进行的研究和技术进步，预计将推动癌症免疫疗法市场的持续增长。

研究涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰了解行业结构，评估全球竞争吸引力。此外，这些工具还对全球癌症免疫疗法市场的各个细分市场进行了全面评估。癌症免疫疗法行业的增长和趋势为本研究提供了一个全面的方法。

区域分析：

该部分涵盖了区域前景，突出了北美、欧洲、亚太、拉美以及中东和非洲地区癌症免疫疗法市场的当前和未来需求。此外，该部分还重点分析了所有主要地区各个应用领域的需求、估计和预测。

该研究还涵盖了市场主要参与者的综合概况以及全球竞争格局的深入分析。The major players in the cancer immunotherapy market include Pfizer Inc, AstraZeneca, Merck & Co., Inc; F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis AG, Lilly, Johnson & Johnson Services, Inc; Immunocore, Ltd.本部分包括竞争格局的整体视图，其中包括各种战略发展，如关键并购、未来能力、合作伙伴关系、财务概况、合作、新产品开发、新产品上市和其他发展。

如果您有任何定制要求，请联系我们。我们的研究团队可以根据您的需求提供定制服务。

目 录

第一章：前言

  • 说明
    • 目标
    • 目标受众
    • 独特销售主张（USP）和产品
  • 研究范围
  • 研究方法
    • 市场调研流程
    • 市场调研方法

第二章：执行摘要

  • 市场亮点
  • 全球市场概况

第三章：癌症免疫疗法-行业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 行业趋势
  • 波特五力分析
  • 市场吸引力分析
    • 按产品分类的市场吸引力分析
    • 市场吸引力分析：按应用
    • 按分销渠道的市场吸引力分析
    • 按最终用途的市场吸引力分析
    • 市场吸引力分析：按地区

第四章：价值链分析

  • 价值链分析
  • 原材料分析
    • 原材料清单
    • 原材料制造商列表
    • 主要原材料价格走势
  • 潜在买家名单
  • 营销渠道
    • 直接营销
    • 间接营销
    • 营销渠道发展趋势

第五章：全球癌症免疫疗法市场分析：按产品分类

  • 产品概述
  • 历史和预测数据
  • 按产品分析
  • 单克隆抗体
  • 免疫调节剂
  • 溶瘤病毒疗法和癌症疫苗

第六章：全球癌症免疫疗法市场分析：按应用分类

  • 概述：按应用
  • 历史和预测数据
  • 分析：按应用
  • 肺癌
  • 乳腺癌
  • 大肠癌
  • 黑色素瘤
  • 前列腺癌
  • 头颈部癌症
  • 卵巢癌
  • 胰腺癌
  • 其他癌症

第七章 ：全球癌症免疫疗法市场分析：按销售渠道划分

  • 分销渠道概述
  • 历史和预测数据
  • 按销售渠道分析
  • 医院药房
  • 零售药店
  • 网上药店

第八章：全球癌症免疫疗法市场分析：按最终用途分类

  • 按最终用途概述
  • 历史和预测数据
  • 按最终用途分析
  • 医院和诊所
  • 癌症研究中心
  • 其他

第九章：全球癌症免疫疗法市场分析：按地域划分

  • 地区展望
  • 产品介绍
  • 北美销售分析
    • 概述、历史和预测数据 销售分析
    • 北美地区销售分析
    • 北美各国销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概述、历史和预测数据 销售分析
    • 欧洲销售分析
    • 欧洲各国销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 意大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概述、历史和预测数据 销售分析
    • 亚太地区细分市场销售分析
    • 亚太地区各国销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳大利亚销售分析
    • 亚太其他地区销售分析
  • 拉丁美洲销售分析
    • 概述、历史和预测数据 销售分析
    • 拉丁美洲各细分市场销售分析
    • 拉丁美洲各国销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概述、历史和预测数据 销售分析
    • 中东及非洲地区销售分析
    • 中东及非洲国家销售分析
    • 沙特阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东和非洲其他地区销售分析

第十章 癌症免疫治疗企业竞争格局

  • 癌症免疫疗法市场竞争
  • 伙伴关系/合作/协议
  • 合并与收购
  • 新产品上市
  • 其他发展

第十一章 ：公司概况

  • 公司份额分析
  • 市场集中率
  • Pfizer Inc
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • AstraZeneca
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • Merck & Co. Inc
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • F. Hoffmann-La Roche Ltd
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • Bristol-Myers Squibb Company
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • Novartis AG
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • Lilly
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • Johnson & Johnson Services Inc
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • Immunocore Ltd
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展

注-在公司概况中，财务细节和近期发展视情况而定，如果是私营公司则可能不包括在内。

Product Code: VMR112111378

The global demand for Cancer Immunotherapy Market is presumed to reach the market size of nearly USD 236.93 BN by 2030 from USD 117.09 BN in 2022 with a CAGR of 9.21% under the study period 2023 - 2030.

Cancer immunotherapy, or immuno-oncology, refers to a treatment approach that utilizes the remarkable capabilities of the body's immune system to combat cancer. The immune system serves as the body's inherent defence mechanism against various diseases, including cancer. It consists of various cells, tissues, and organs that work together to identify and destroy abnormal cells, including cancer cells.

MARKET DYNAMICS:

The cancer immunotherapy market is witnessing significant growth due to several key factors. First, there is a rising incidence of cancer worldwide, driving the demand for effective treatment options. Immunotherapy, with its potential to target various types of cancers, has emerged as a promising solution. Second, the favourable clinical outcomes of immunotherapy, including improved survival rates and long-term outcomes, have boosted its adoption. Third, advancements in immunotherapy techniques, such as the discovery of novel targets and the development of combination therapies, have enhanced treatment efficacy. Government initiatives, funding support, and streamlined regulatory processes have also played a crucial role in fueling market growth. Furthermore, collaborations and partnerships between pharmaceutical companies and research institutions have accelerated innovation in the field. Increased investment and market competition have resulted in the development of diverse immunotherapeutic agents. The personalized medicine approach, where treatments are tailored to individual patients, has further propelled the market. Additionally, expanded indications and approvals of immunotherapeutic agents have widened the potential patient population. Overall, these factors, coupled with ongoing research and technological advancements, are expected to drive continued growth in the cancer immunotherapy market.

The research covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cancer immunotherapy. The growth and trends of cancer immunotherapy industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the cancer immunotherapy market provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Monoclonal Antibodies
  • Immunomodulators
  • Oncolytic Viral Therapies & Cancer Vaccines

By Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head & Neck Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End Use

  • Hospitals & Clinics
  • Cancer Research Centers
  • Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Cancer Immunotherapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cancer immunotherapy market include Pfizer Inc, AstraZeneca, Merck & Co., Inc; F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis AG, Lilly, Johnson & Johnson Services, Inc; Immunocore, Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CANCER IMMUNOTHERAPY - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By End Use
    • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY PRODUCT

  • 5.1 Overview by Product
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Product
  • 5.4 Monoclonal Antibodies Historic and Forecast Sales by Regions
  • 5.5 Immunomodulators Historic and Forecast Sales by Regions
  • 5.6 Oncolytic Viral Therapies & Cancer Vaccines Historic and Forecast Sales by Regions

6 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY APPLICATION

  • 6.1 Overview by Application
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Application
  • 6.4 Lung Cancer Historic and Forecast Sales by Regions
  • 6.5 Breast Cancer Historic and Forecast Sales by Regions
  • 6.6 Colorectal Cancer Historic and Forecast Sales by Regions
  • 6.7 Melanoma Historic and Forecast Sales by Regions
  • 6.8 Prostate Cancer Historic and Forecast Sales by Regions
  • 6.9 Head & Neck Cancer Historic and Forecast Sales by Regions
  • 6.10. Ovarian Cancer Historic and Forecast Sales by Regions
  • 6.11 Pancreatic Cancer Historic and Forecast Sales by Regions
  • 6.12 Others Historic and Forecast Sales by Regions

7 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1 Overview by Distribution Channel
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Distribution Channel
  • 7.4 Hospital Pharmacy Historic and Forecast Sales by Regions
  • 7.5 Retail Pharmacy Historic and Forecast Sales by Regions
  • 7.6 Online Pharmacy Historic and Forecast Sales by Regions

8 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY END USE

  • 8.1 Overview by End Use
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End Use
  • 8.4 Hospitals & Clinics Historic and Forecast Sales by Regions
  • 8.5 Cancer Research Centers Historic and Forecast Sales by Regions
  • 8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL CANCER IMMUNOTHERAPY MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CANCER IMMUNOTHERAPY COMPANIES

  • 10.1. Cancer Immunotherapy Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF CANCER IMMUNOTHERAPY INDUSTRY

  • 11.1. Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Pfizer Inc
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. AstraZeneca
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Merck & Co. Inc
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. F. Hoffmann-La Roche Ltd
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. Bristol-Myers Squibb Company
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. Novartis AG
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Lilly
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Johnson & Johnson Services Inc
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Immunocore Ltd
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Product (USD MN)
  • Monoclonal Antibodies Market Sales by Geography (USD MN)
  • Immunomodulators Market Sales by Geography (USD MN)
  • Oncolytic Viral Therapies & Cancer Vaccines Market Sales by Geography (USD MN)
  • Analysis Market by Application (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Breast Cancer Market Sales by Geography (USD MN)
  • Colorectal Cancer Market Sales by Geography (USD MN)
  • Melanoma Market Sales by Geography (USD MN)
  • Prostate Cancer Market Sales by Geography (USD MN)
  • Head & Neck Cancer Market Sales by Geography (USD MN)
  • Ovarian Cancer Market Sales by Geography (USD MN)
  • Pancreatic Cancer Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales by Geography (USD MN)
  • Retail Pharmacy Market Sales by Geography (USD MN)
  • Online Pharmacy Market Sales by Geography (USD MN)
  • Analysis by End Use (USD MN)
  • Hospitals & Clinics Market Sales by Geography (USD MN)
  • Cancer Research Centers Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Cancer Immunotherapy Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Cancer Immunotherapy
  • Market Research Process
  • Market Research Methodology
  • Global Cancer Immunotherapy Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Product
  • Market Attractiveness Analysis by Application
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by End Use
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Product (USD MN)
  • Monoclonal Antibodies Market Sales by Geography (USD MN)
  • Immunomodulators Market Sales by Geography (USD MN)
  • Oncolytic Viral Therapies & Cancer Vaccines Market Sales by Geography (USD MN)
  • Global Market Analysis by Application (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Breast Cancer Market Sales by Geography (USD MN)
  • Colorectal Cancer Market Sales by Geography (USD MN)
  • Melanoma Market Sales by Geography (USD MN)
  • Prostate Cancer Market Sales by Geography (USD MN)
  • Head & Neck Cancer Market Sales by Geography (USD MN)
  • Ovarian Cancer Market Sales by Geography (USD MN)
  • Pancreatic Cancer Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales by Geography (USD MN)
  • Retail Pharmacy Market Sales by Geography (USD MN)
  • Online Pharmacy Market Sales by Geography (USD MN)
  • Global Market Analysis by End Use (USD MN)
  • Hospitals & Clinics Market Sales by Geography (USD MN)
  • Cancer Research Centers Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the and are not limited to the TOC.